Brief: Race Oncology Says US FDA Orphan Drug Designation Awarded To RC220 Bisantrene
11/06/2024 02:51
June 11 (Reuters) - Race Oncology Ltd RAC.AX :
* US FDA ORPHAN DRUG DESIGNATION AWARDED TO RC220 BISANTRENE
Further company coverage: RAC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220